We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.79 | -0.62% | 127.47 | 128.48 | 127.18 | 128.11 | 6,221,929 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Merck & Co. on Wednesday said a phase 3 study of its cancer drug Keytruda in combination with chemotherapy met one of its dual primary endpoints in a form of triple-negative breast cancer.
The Kenilworth, N.J., drug maker said the combination showed a statistically significant and clinically meaningful improvement in progression-free survival in patients with metastatic triple-negative breast cancer whose tumors expressed PD-L1.
Merck said the study will continue without changes to evaluate the other primary endpoint of overall survival.
The company said Keytruda's safety profile in the trial was consistent with previous studies, with no new safety signals identified.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 12, 2020 07:27 ET (12:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
